CA2612215A1 - Device for the time-controlled intravenous administering of the anesthetic propofol - Google Patents
Device for the time-controlled intravenous administering of the anesthetic propofol Download PDFInfo
- Publication number
- CA2612215A1 CA2612215A1 CA002612215A CA2612215A CA2612215A1 CA 2612215 A1 CA2612215 A1 CA 2612215A1 CA 002612215 A CA002612215 A CA 002612215A CA 2612215 A CA2612215 A CA 2612215A CA 2612215 A1 CA2612215 A1 CA 2612215A1
- Authority
- CA
- Canada
- Prior art keywords
- propofol
- time
- profile
- parameters
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 title claims abstract description 87
- 229960004134 propofol Drugs 0.000 title claims abstract description 84
- 230000003444 anaesthetic effect Effects 0.000 title claims abstract description 29
- 238000001990 intravenous administration Methods 0.000 title abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 43
- 230000000694 effects Effects 0.000 claims description 32
- 210000004556 brain Anatomy 0.000 claims description 27
- 230000003285 pharmacodynamic effect Effects 0.000 claims description 19
- 238000004088 simulation Methods 0.000 claims description 19
- 210000000056 organ Anatomy 0.000 claims description 18
- 230000017531 blood circulation Effects 0.000 claims description 13
- 230000037396 body weight Effects 0.000 claims description 13
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- 230000001419 dependent effect Effects 0.000 claims description 10
- 230000002068 genetic effect Effects 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 7
- 238000005457 optimization Methods 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000001802 infusion Methods 0.000 abstract description 31
- 206010002091 Anaesthesia Diseases 0.000 description 30
- 230000037005 anaesthesia Effects 0.000 description 30
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 208000003443 Unconsciousness Diseases 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 210000002381 plasma Anatomy 0.000 description 13
- 230000006698 induction Effects 0.000 description 12
- 230000036470 plasma concentration Effects 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 238000001949 anaesthesia Methods 0.000 description 4
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 229960001391 alfentanil Drugs 0.000 description 3
- 238000011067 equilibration Methods 0.000 description 3
- 238000002695 general anesthesia Methods 0.000 description 3
- 238000012905 input function Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000001272 nitrous oxide Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 208000028208 end stage renal disease Diseases 0.000 description 2
- 201000000523 end stage renal failure Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000037323 metabolic rate Effects 0.000 description 2
- 210000003657 middle cerebral artery Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241001535291 Analges Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000030939 Bubalus bubalis Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000700112 Chinchilla Species 0.000 description 1
- 206010010317 Congenital absence of bile ducts Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 241000283014 Dama Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000282330 Procyon lotor Species 0.000 description 1
- 241000283011 Rangifer Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 201000005271 biliary atresia Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000000332 black box Nutrition 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002773 propofol effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Medicinal Chemistry (AREA)
- Anesthesiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Databases & Information Systems (AREA)
- Vascular Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Data Mining & Analysis (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005028080A DE102005028080A1 (de) | 2005-06-17 | 2005-06-17 | Verfahren zur zeitlich gesteuerten intravenösen Verabreichung des Narkosemittels Propofol |
| DE102005028080.3 | 2005-06-17 | ||
| PCT/EP2006/005340 WO2006133825A1 (de) | 2005-06-17 | 2006-06-03 | Vorrichtung zur zeitlich gesteuerten intravenösen verabreichung des narkosemittels propofol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2612215A1 true CA2612215A1 (en) | 2006-12-21 |
Family
ID=36940350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002612215A Abandoned CA2612215A1 (en) | 2005-06-17 | 2006-06-03 | Device for the time-controlled intravenous administering of the anesthetic propofol |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8038645B2 (ja) |
| EP (1) | EP1904940A1 (ja) |
| JP (1) | JP5033794B2 (ja) |
| AU (1) | AU2006257418B2 (ja) |
| CA (1) | CA2612215A1 (ja) |
| DE (1) | DE102005028080A1 (ja) |
| WO (1) | WO2006133825A1 (ja) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004010516A1 (de) * | 2004-03-04 | 2005-09-22 | Bayer Technology Services Gmbh | Verbessertes Verfahren zur zeitlichen Dosierung von Arzneistoffen |
| EP2029197A2 (en) * | 2006-06-21 | 2009-03-04 | Universität Bern | A system for controlling administration of anaesthesia |
| US20090270694A1 (en) * | 2008-04-24 | 2009-10-29 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for monitoring and modifying a combination treatment |
| US20100130811A1 (en) * | 2008-04-24 | 2010-05-27 | Searete Llc | Computational system and method for memory modification |
| US9064036B2 (en) * | 2008-04-24 | 2015-06-23 | The Invention Science Fund I, Llc | Methods and systems for monitoring bioactive agent use |
| US20090271009A1 (en) * | 2008-04-24 | 2009-10-29 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Combination treatment modification methods and systems |
| US9649469B2 (en) * | 2008-04-24 | 2017-05-16 | The Invention Science Fund I Llc | Methods and systems for presenting a combination treatment |
| US20100280332A1 (en) * | 2008-04-24 | 2010-11-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for monitoring bioactive agent use |
| US20100041964A1 (en) * | 2008-04-24 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for monitoring and modifying a combination treatment |
| US9282927B2 (en) | 2008-04-24 | 2016-03-15 | Invention Science Fund I, Llc | Methods and systems for modifying bioactive agent use |
| US20100004762A1 (en) * | 2008-04-24 | 2010-01-07 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational system and method for memory modification |
| US20090270688A1 (en) * | 2008-04-24 | 2009-10-29 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for presenting a combination treatment |
| US20090271122A1 (en) * | 2008-04-24 | 2009-10-29 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for monitoring and modifying a combination treatment |
| US9026369B2 (en) * | 2008-04-24 | 2015-05-05 | The Invention Science Fund I, Llc | Methods and systems for presenting a combination treatment |
| US20100069724A1 (en) * | 2008-04-24 | 2010-03-18 | Searete Llc | Computational system and method for memory modification |
| US9662391B2 (en) | 2008-04-24 | 2017-05-30 | The Invention Science Fund I Llc | Side effect ameliorating combination therapeutic products and systems |
| US20090312668A1 (en) * | 2008-04-24 | 2009-12-17 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational system and method for memory modification |
| US20090271375A1 (en) * | 2008-04-24 | 2009-10-29 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Combination treatment selection methods and systems |
| US9449150B2 (en) * | 2008-04-24 | 2016-09-20 | The Invention Science Fund I, Llc | Combination treatment selection methods and systems |
| US20100022820A1 (en) * | 2008-04-24 | 2010-01-28 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational system and method for memory modification |
| US9239906B2 (en) * | 2008-04-24 | 2016-01-19 | The Invention Science Fund I, Llc | Combination treatment selection methods and systems |
| US20100015583A1 (en) * | 2008-04-24 | 2010-01-21 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational System and method for memory modification |
| US20090271347A1 (en) * | 2008-04-24 | 2009-10-29 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for monitoring bioactive agent use |
| US8876688B2 (en) * | 2008-04-24 | 2014-11-04 | The Invention Science Fund I, Llc | Combination treatment modification methods and systems |
| US20100100036A1 (en) * | 2008-04-24 | 2010-04-22 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational System and Method for Memory Modification |
| US20100125561A1 (en) * | 2008-04-24 | 2010-05-20 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational system and method for memory modification |
| US20100081861A1 (en) * | 2008-04-24 | 2010-04-01 | Searete Llc | Computational System and Method for Memory Modification |
| US20090312595A1 (en) * | 2008-04-24 | 2009-12-17 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | System and method for memory modification |
| US20090269329A1 (en) * | 2008-04-24 | 2009-10-29 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Combination Therapeutic products and systems |
| US9560967B2 (en) * | 2008-04-24 | 2017-02-07 | The Invention Science Fund I Llc | Systems and apparatus for measuring a bioactive agent effect |
| US8930208B2 (en) * | 2008-04-24 | 2015-01-06 | The Invention Science Fund I, Llc | Methods and systems for detecting a bioactive agent effect |
| US20100063368A1 (en) * | 2008-04-24 | 2010-03-11 | Searete Llc, A Limited Liability Corporation | Computational system and method for memory modification |
| US20100041958A1 (en) * | 2008-04-24 | 2010-02-18 | Searete Llc | Computational system and method for memory modification |
| US20100017001A1 (en) * | 2008-04-24 | 2010-01-21 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational system and method for memory modification |
| US8798701B2 (en) | 2008-09-30 | 2014-08-05 | Drexel University | Functional near-infrared spectroscopy as a monitor for depth of anesthesia |
| DE102009056726B4 (de) | 2009-12-04 | 2012-02-02 | Khs Gmbh | Verfahren und Vorrichtung zur Aufbereitung von im Zuge einer Behälterreinigung anfallender Prozessflüssigkeit |
| US10388405B2 (en) | 2013-03-22 | 2019-08-20 | Massachusetts Institute Of Technology | Systems and methods for predicting adverse events and assessing level of sedation during medical procedures |
| US9849241B2 (en) | 2013-04-24 | 2017-12-26 | Fresenius Kabi Deutschland Gmbh | Method of operating a control device for controlling an infusion device |
| JP6148946B2 (ja) * | 2013-09-09 | 2017-06-14 | 日本光電工業株式会社 | 表示装置、表示装置の作動方法、および表示装置の制御プログラム |
| EP3120885B1 (en) * | 2014-03-20 | 2024-07-31 | Terumo Kabushiki Kaisha | Liquid delivery pump |
| DE102014105058A1 (de) * | 2014-04-09 | 2015-10-15 | Stephanie Ittstein | Vorrichtung zu einer Herstellung und/oder zu einer Verabreichung |
| WO2016102463A1 (en) | 2014-12-23 | 2016-06-30 | Bosteels Arnaud | Combination of remifentanil and propofol |
| WO2017027855A1 (en) | 2015-08-12 | 2017-02-16 | Massachusetts Institute Of Technology | Systems and methods for predicting adverse events and assessing level of sedation during medical procedures |
| JP7002472B2 (ja) * | 2016-05-02 | 2022-02-04 | フレゼニウス ヴィアル エスアーエス | 患者に対するプロポフォールの投与を制御する方法及び制御デバイス |
| CN107585890B (zh) * | 2017-09-22 | 2020-07-24 | 天津大学 | 基于蒙特卡罗模拟的新兴污染物污水优化处理方法 |
| GB2589298B (en) | 2019-10-02 | 2023-08-09 | Nottingham Univ Hospitals Nhs Trust | Patient-Maintained Sedation |
| DE102021110371A1 (de) | 2021-04-22 | 2022-10-27 | Medicad Hectec Gmbh | Verfahren zur Planung der Dosierung eines Anästhetikums zur Herbeiführung eines Zustands der Anästhesie |
| CN115105681B (zh) * | 2022-06-24 | 2024-05-24 | 纽锐思(苏州)医疗科技有限公司 | 基于多模态生理指标的麻醉闭环输注系统 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5609575A (en) | 1994-04-11 | 1997-03-11 | Graseby Medical Limited | Infusion pump and method with dose-rate calculation |
| US5687208A (en) * | 1995-10-06 | 1997-11-11 | Bhb General Partnership | Method of and apparatus for predicting computed tomography contrast enhancement with feedback |
| US5870697A (en) * | 1996-03-05 | 1999-02-09 | The Regents Of The University Of California | Calculation of radiation therapy dose using all particle Monte Carlo transport |
| US5775330A (en) * | 1996-07-22 | 1998-07-07 | Battelle Memorial Institute | Neurometric assessment of intraoperative anesthetic |
| US6016444A (en) * | 1997-12-10 | 2000-01-18 | New York University | Automatic control of anesthesia using quantitative EEG |
| DE10160270A1 (de) * | 2001-12-07 | 2003-06-26 | Bayer Ag | Computersystem und Verfahren zur Berechnung von ADME-Eigenschaften |
| DE10256315A1 (de) * | 2002-12-03 | 2004-06-17 | Bayer Ag | Computersystem und Verfahren zur Berechnung eines pharmakokinetischen Verhaltens einer chemischen Substanz in Insekten |
| US20040172330A1 (en) | 2003-02-06 | 2004-09-02 | Gibson J. Edward | Business method and apparatus for advertising and fundraising |
| US8249813B2 (en) * | 2003-05-22 | 2012-08-21 | Brainlab Ag | System and process for metabolic guidance of introduced cellular material |
| US8998808B2 (en) * | 2003-06-19 | 2015-04-07 | Wayne State University | System for identifying patient response to anesthesia infusion |
| DE10345837A1 (de) | 2003-10-02 | 2005-04-21 | Bayer Technology Services Gmbh | Verfahren zur Bestimmung einer Wirkstoffdosierung |
| DE10345836A1 (de) * | 2003-10-02 | 2005-04-21 | Bayer Technology Services Gmbh | Verfahren zur Simulation der Wechselwirkung von chemischen Substanzen mit lebenden Organismen |
| FR2862536B1 (fr) | 2003-11-21 | 2007-11-23 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques |
| WO2005075274A1 (de) | 2004-02-09 | 2005-08-18 | Thyssenkrupp Presta Steertec Gmbh | Hydraulische lenkung mit geregelter pumpe |
| DE102004010516A1 (de) | 2004-03-04 | 2005-09-22 | Bayer Technology Services Gmbh | Verbessertes Verfahren zur zeitlichen Dosierung von Arzneistoffen |
| DE102004025534A1 (de) * | 2004-05-25 | 2005-12-15 | Bayer Technology Services Gmbh | Verfahren zur (zweistufigen) Dosis- und Dosierungsfindung |
| DE102006028232A1 (de) * | 2006-06-20 | 2007-12-27 | Bayer Technology Services Gmbh | Vorrichtung und Verfahren zur Berechnung und Bereitstellung einer Medikamentendosis |
-
2005
- 2005-06-17 DE DE102005028080A patent/DE102005028080A1/de not_active Withdrawn
-
2006
- 2006-06-03 JP JP2008516175A patent/JP5033794B2/ja not_active Expired - Fee Related
- 2006-06-03 WO PCT/EP2006/005340 patent/WO2006133825A1/de active Application Filing
- 2006-06-03 AU AU2006257418A patent/AU2006257418B2/en not_active Ceased
- 2006-06-03 US US11/917,452 patent/US8038645B2/en not_active Expired - Fee Related
- 2006-06-03 CA CA002612215A patent/CA2612215A1/en not_active Abandoned
- 2006-06-03 EP EP06743110A patent/EP1904940A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008546435A (ja) | 2008-12-25 |
| JP5033794B2 (ja) | 2012-09-26 |
| US20100094202A1 (en) | 2010-04-15 |
| AU2006257418B2 (en) | 2011-07-14 |
| AU2006257418A1 (en) | 2006-12-21 |
| US8038645B2 (en) | 2011-10-18 |
| EP1904940A1 (de) | 2008-04-02 |
| WO2006133825A1 (de) | 2006-12-21 |
| DE102005028080A1 (de) | 2006-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2006257418B2 (en) | Device for the time-controlled intravenous administering of the anesthetic propofol | |
| JP4560081B2 (ja) | 薬剤の計時投薬の改良された方法 | |
| Cesarovic et al. | Isoflurane and sevoflurane provide equally effective anaesthesia in laboratory mice | |
| Wu et al. | Utilizing the modified T-maze to assess functional memory outcomes after cardiac arrest | |
| Shepard et al. | Pharmacodynamics of alfaxalone after single‐dose intramuscular administration in red‐eared sliders (Trachemys scripta elegans): a comparison of two different doses at two different ambient temperatures | |
| RU2713972C1 (ru) | Управляющее устройство для управления введением пропофола для пациента | |
| Hecht et al. | Alterations in the reinforcing efficacy of cocaine in adult rats following prenatal exposure to cocaine. | |
| Herrero et al. | Closed-loop control for precision antimicrobial delivery: an in silico proof-of-concept | |
| Lunze et al. | Analysis and modelling of glucose metabolism in diabetic Göttingen Minipigs | |
| US20180280620A1 (en) | Shivering adjustment infusion system and method | |
| Galante et al. | Comparison between total intravenous anesthesia with propofol and intermittent bolus of tiletamine-zolazepam in capuchin monkey (Sapajus apella) | |
| Pautassi et al. | Acute ethanol counteracts the acquisition of aversive olfactory learning in infant rats | |
| Sidorova et al. | Ecological and physiological assessment of animal anesthesia methods | |
| Roguski et al. | Fostering itself increases nicotine self-administration in young adult male rats | |
| Lunze et al. | Preliminary results of a type-1 diabetes swine model | |
| Wargent | Practical Considerations for In Vivo Mouse Studies | |
| Chen et al. | ED50 and ED95 of rocuronium during alfaxalone anesthesia in dogs | |
| Coetzee et al. | Assessment of the clinical validity of an adjusted Marsh pharmacokinetic model using an effect-site rate constant (ke0) of 1.21 min-1 | |
| Revillo et al. | Odor-avoidance or odor-preference induced by amphetamine in the infant rat depending on the dose and testing modality | |
| Liu | Closed-Loop or Automated Titration of Intravenous Anesthesia: Background, Science, and Clinical Impact | |
| Letscher et al. | An Experimental Study to Optimize Neuromuscular Blockade Protocols in Cynomolgus Macaques: Monitoring, Doses, and Antagonism | |
| Bardol | Pharmacokinetic/pharmacodynamic modelling to optimize the dose of analgesics and sedatives in children | |
| Zeiler | Anaesthetic, analgesic and cardiorespiratory effects of three intramuscular anaesthetic protocols in cats | |
| Schwieger et al. | New developments in our understanding of the pharmacokinetics and pharmacodynamics of the opioids | |
| Absalom | Intravenous Infusions for Sedation: Rationale, State of the Art, and Future Trends |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20140603 |